Comparative Effects of Irbesartan Versus Amlodipine on Left Ventricular Mass Index in Hypertensive Patients with Left Ventricular Hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 5, 2003, Pages 622-628

  Gaudio, Carlo ^a,c   Ferri, Fabio Massimo ^a   Giovannini, Marco ^a   Pannarale, Giuseppe ^a   Puddu, Paolo Emilio ^a   Vittore, Alessandro ^a   Fera, Maria Stella ^b   Vizza, Carmine Dario ^a   Fedele, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Amlodipine; Echocardiography; Hypertension; Irbesartan; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; CALCIUM ANTAGONIST; IRBESARTAN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TITRIMETRY;

ADULT; AGED; AMLODIPINE; ANALYSIS OF VARIANCE; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 0142200901     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200311000-00007     Document Type: Article

References (52)

1. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med. 1980;69:576-584.
2. Folkow B. The Fourth Volhaard Lecture: cardiovascular structural adaptation-its role in initiation and maintenance of primary hypertension. Clin Sci Mol Med. 1987;55:3S-22S.
3. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insight from the Framingham study. J Cardiovasc Pharmacol. 1987;10:S135-S140.
4. McLenachan JM, Henderson E, Morris KL, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. New Engl J Med. 1987;317:787-792.
5. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med. 1990;322:1561-1566.
6. Dunn FG, Pfeffer MA. Left ventricular hypertrophy in hypertension. N Engl J Med. 1999;340:1279-1280.
7. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
8. Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double blind studies until December 1996). Nephrol Dial Transplant. 1998;13:564-569.
9. Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. J Hypertens. 1998;16:S29-S34.
10. Cruickshank J, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
11. Gosse P, Dallocchio M. La regression de l'hypertrophie ventriculaire gauche chez l'hypertendu. Paris, France: Editions Medecine Pratique; 1992.
12. Koren MJ, Ulin RJ, Laragh JH, et al. Reduction of the left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens. 1991;4:1A.
13. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: multicentre trial. Am J Hypertens. 1992;5:182S-189S.
14. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
15. Muiesan ML, Salvetti M, Tizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1105.
16. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
17. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation. 1997;95:1983-1985.
18. The Sixth Report of the Joint National Committee On Prevention. Detection, Evaluation and Treatment of High Blood Pressure (JNV VI). Arch Intern Med. 1997;157:2413-2446.
19. Kloner RA, Sower JR, Di Bona GF, et al, for the ACCT Study Group. Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. J Cardiovasc Pharmacol. 1995;26:471-476.
20. Hansson L, Hedner T, Dahlof B. Prospective, Randomized, Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Press. 1992;1:113-119.
21. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiography assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
22. Shan DJ, De Maria A, Kisslo J, et al. The Committee on M-Mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-Mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
23. Kent RL, Mann DL, Cooper G. Signals for cardiac muscle hypertrophy in hypertension. J Cardiovasc Pharmacol. 1991;17:S7-S13.
24. Long CS, Kariya K, Karns L, et al. Sympathetic activity: modulator of myocardial hypertrophy. J Cardiovasc Pharmacol. 1991;17:S20-S4.
25. Zabalgoitia M. Left ventricular mass and function in primary hypertension. Am J Hypertens. 1996;9:55S-59S.
26. Gaudio C, Tanzilli G, Collatina S, et al. Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with captopril as assessed by magnetic resonance imaging. Cardiologia. 1992;37:789-791.
27. Gaudio C, Tanzilli C, Ferri FM, et al. Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. J Cardiovasc Pharmacol. 1998;32:760-768.
28. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in moderate hypertension: comparison of six antihypertensive agents. Circulation. 1997;95:2007-2014.
29. Beltman FW, Heesen WF, Smit AJ, et al. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press. 1998;7:109-117.
30. Adalet K, Mercanoglu F, Orak E, et al. The effect of amlodipine on the mass and function of the left ventricle in patients with primary hypertension and left ventricular hypertrophy. Curr Ther Res Clin Exp. 1995;56:607-614.
31. Fak AS, Okucu M, Tezcan H, et al. The effects of amlodipine on left ventricular mass and diastolic function in concentric and eccentric left ventricular hypertrophy. J Cardiovasc Pharmacol Ther. 1996;1:95-100.
32. Singh NK, Gupta SK, Agrawal BV. Left ventricular mass regression with amlodipine in elderly hypertensives. Clin Exp Hypertens. 1999;21:113-119.
33. Islim IF, Watson RD, Ihenacho HN, et al. Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. Cardiology. 2001;96:10-18.
34. Sadoshima J, Izuno S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblast. Circulation. 1993;73:413-423.
35. Schunkert H, Hense HW, Muscholl M, et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997;77:24-31.
36. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:2348-2357.
37. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649-1654.
38. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safe against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
39. Pool JL, Guthrie RM, Littlejohn TW III, et al. Weir MR Wilson TW, Wright J, Kassler-Taub KB, Reeves RA: Dose-Related Antihypertensive Effects of Irbesartan in Patients With Mild-to-Moderate Hypertension. Am J Hypertens. 1998;11:462-470.
40. Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3:295-302.
41. Ishimitsu T, Minami J, Yoshii M, et al. Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients. Clin Exp Hypertens. 2002;24:41-50.
42. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
43. Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press. 1998;7:31-37.
44. Mimran A, Ruilope L, Kerwin L, et al. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12:203-208.
45. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mildto-moderate hypertension. Irbesartan Losartan Study Investigators. Am J Hypertens. 1998;11:445-453.
46. Littlejohn T III, Saini R, Kassler-Taub K, et al. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. Clin Exp Hypertens. 1999;21:1273-1295.
47. Dahlof B, Devereux RB, Kjeldsen SE, et al. et al for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
48. Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension. Circulation. 1998;98:2037-2042.
49. Thurmann PA. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovasc Pharmacol. 1999;33:S33-S36.
50. Martina B, Dieterle T, Weinbacher M, et al. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology. 1999;92:110-114.
51. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167-1176.
52. Dahlof B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens. 2001;14:174-182.